Decoy Biosystems, a San Diego, California-based cancer immunotherapy company, raised $6.0m in seed funding.
Backers included Mountain Pacific Venture Fund, TY BIO Investment, Inc., a California-based wholly-owned subsidiary of Tongyang Networks, a South Korean KOSPI-listed company, and angel investors.
The company intends to use the funds to advance its technology for unresectable or metastatic solid tumors and lymphoma.
Decoy Biosystems is a biotechnology company developing a novel and potentially best in class, multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy. The company is dedicated to enhancing the expanding curative cancer immunology for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for approximately 90 percent of all cancer deaths.
Decoy Biosystems was recently accepted into the Johnson & Johnson Innovation, JLABS (JLABS) life science incubator.
FinSMEs
23/10/2018